Sabra Health Care price target raised to $19 from $18 at Scotiabank
Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SBRA:
Disclaimer & DisclosureReport an Issue
Sabra Health Care REIT Reports Strong Q1 2025 Results
Sabra Healthcare REIT Reports Record Highs and Strong Pipeline
Hold Rating on Sabra Healthcare REIT Amid Strong Financials and Strategic Uncertainties
Sabra Healthcare REIT Expands Senior Housing Portfolio
Sabra Health Care reports Q1 FFO 37c, consensus 36c
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
2 days ago
- Business Wire
Sabra Health Care REIT, Inc. Announces Second Quarter 2025 Earnings Release Date and Conference Call
TUSTIN, Calif.--(BUSINESS WIRE)-- Sabra Health Care REIT, Inc. (Nasdaq: SBRA) announced today that it will issue its 2025 second quarter earnings release on August 4, 2025, after the close of trading. A conference call with a simultaneous webcast to discuss the 2025 second quarter results will be held on Tuesday, August 5th at 10:00 a.m. Pacific Time. Share A conference call with a simultaneous webcast to discuss the 2025 second quarter results will be held on Tuesday, August 5 th at 10:00 a.m. Pacific Time. The dial-in number for U.S. participants is 888-880-4448. For participants outside the U.S., the dial-in number is 646-960-0572. The conference ID number is 1382596. The webcast URL is A digital replay of the call will be available on our website at About Sabra Sabra Health Care REIT, Inc., a Maryland corporation, operates as a self-administered, self-managed real estate investment trust (a "REIT") that, through its subsidiaries, owns and invests in real estate serving the healthcare industry throughout the United States and Canada.
Business Insider
16-07-2025
- Business Insider
Boston Properties (BXP) Receives a Hold from Morgan Stanley
Morgan Stanley analyst Ronald Kamdem maintained a Hold rating on Boston Properties today and set a price target of $65.00. The company's shares closed today at $69.92. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Kamdem covers the Real Estate sector, focusing on stocks such as Macerich, Realty Income, and Gaming and Leisure. According to TipRanks, Kamdem has an average return of 4.1% and a 53.11% success rate on recommended stocks. In addition to Morgan Stanley, Boston Properties also received a Hold from Scotiabank's Nicholas Yulico in a report issued yesterday. However, on the same day, Mizuho Securities maintained a Buy rating on Boston Properties (NYSE: BXP). Based on Boston Properties' latest earnings release for the quarter ending March 30, the company reported a quarterly revenue of $865.22 million and a net profit of $61.18 million. In comparison, last year the company earned a revenue of $839.44 million and had a net profit of $79.88 million
Business Insider
13-07-2025
- Business Insider
Wells Fargo Sticks to Its Buy Rating for Sabra Healthcare REIT (SBRA)
Wells Fargo analyst maintained a Buy rating on Sabra Healthcare REIT on July 11 and set a price target of $20.00. The company's shares closed last Friday at $18.46. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Currently, the analyst consensus on Sabra Healthcare REIT is a Moderate Buy with an average price target of $19.40, which is a 5.09% upside from current levels. In a report released on July 8, Bank of America Securities also reiterated a Buy rating on the stock with a $20.00 price target. The company has a one-year high of $20.03 and a one-year low of $15.60. Currently, Sabra Healthcare REIT has an average volume of 2.55M. Based on the recent corporate insider activity of 68 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of SBRA in relation to earlier this year. Most recently, in May 2025, Michael J Foster, a Director at SBRA sold 11,000.00 shares for a total of $200,310.00.
